|
    ATNX U.S.: Nasdaq

    Athenex Inc.

    ATNXUS
    Open
    Back To Top
    Last Updated: Jun 23, 2021 11:50 a.m. EDT Real time quote

    $ 4.7335

    0.0135 0.29%
    Previous Close
    $4.7200
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 337.58K 65 Day Avg: 5.43M
    6% vs Avg
    4.6900 Day Range 4.8700
    3.6600 52 Week Range 15.2400

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ATNX Overview

    Performance

    5 Day
    • -1.18%
    1 Month
    • 0.50%
    3 Month
    • 11.90%
    YTD
    • -57.20%
    1 Year
    • -63.22%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 7 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    Athenex Partner Gets Positive CHMP Opinion for Klisyri Tirbanibulin

    Athenex downgraded to perform from outperform at Oppenheimer

    Athenex downgraded to hold from buy at Truist

    Athenex stock plunges to pace all decliners after disappointing FDA response to breast cancer treatment NDA

    Athenex started at outperform at Evercore ISI

    Athenex started at outperform with $22 stock price target at SVB Leerink

    Read full story

    A Biotech Pro Bought Up These 3 Stocks

    Athenex shares fall 19% in morning trading

    Athenex started at buy with $28 stock price target at SunTrust RH

    Read full story

    A Biotech Pro Loaded Up on These 2 Stocks

    Athenex started at buy with $20 stock price target at SunTrust RH

    Athenex's profit and revenue disappoint

    Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints

    Athenex's stock soars in its public debut

    Athenex's stock to debut on the Nasdaq after pricing IPO to raise $66 million

    Athenex prices IPO at $11 a share to raise $66 mln

    • Other News
    • Press Releases

    Oppenheimer Maintains Their Hold Rating on Athenex (ATNX)

    on SmarterAnalyst

    Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

    on Zacks.com

    Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

    on Zacks.com

    Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases

    on Zacks.com

    Athenex, Inc. (ATNX) Q1 2021 Earnings Call Transcript

    on Motley Fool

    Athenex (ATNX) Gets a Hold Rating from Oppenheimer

    on SmarterAnalyst

    Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

    on Zacks.com

    Why Athenex Stock Skyrocketed Today

    on Motley Fool

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

    on InvestorPlace.com

    Athenex Snaps Up Kuur Therapeutics For $185M; Street Sees 133.7% Upside

    on TipRanks.com

    7 Penny Stocks That Wall Street Thinks Are Undervalued

    on InvestorPlace.com

    Athenex (ATNX) was Downgraded to a Hold Rating at Leerink Partners

    on SmarterAnalyst

    What Made Needham Downgrade Athenex’s Stock?

    on SmarterAnalyst

    ATNX Stock Alert: The FDA News That Has Athenex Shares Plunging Monday

    on InvestorPlace.com

    Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates

    on Zacks.com

    Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

    on Zacks.com

    Athenex (ATNX) Received its Third Buy in a Row

    on SmarterAnalyst

    Top Insider Buys Highlight for the Week of Nov. 6

    on GuruFocus.com

    Athenex (ATNX) Receives a Buy from Oppenheimer

    on SmarterAnalyst

    Needham Reiterates a Buy Rating on Athenex (ATNX)

    on SmarterAnalyst

    Athenex Inc.

    Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

    Competitors

    Name Chg % Market Cap
    Ono Pharmaceutical Co. Ltd. ADR -0.40% $11.33B
    Oncolix Inc. 0.00% $512.26
    Omeros Corp. -0.26% $963.6M
    Competitor Data Provided ByCapital Cube Logo